Cargando…

Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration

(1) Background: Psoriasis (PS) is a common immune-mediated disease of the skin with possible extension to joints, aorta and eye. Myocardial inflammation has rarely been suggested. (2) Aims: Report of PS-related myocarditis. (3) Methods and Results: One hundred consecutive patients with PS were scree...

Descripción completa

Detalles Bibliográficos
Autores principales: Frustaci, Andrea, Galea, Nicola, Dominici, Lorenzo, Verardo, Romina, Alfarano, Maria, Scialla, Rossella, Richetta, Antonio Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299195/
https://www.ncbi.nlm.nih.gov/pubmed/37373705
http://dx.doi.org/10.3390/jcm12124010
_version_ 1785064303740583936
author Frustaci, Andrea
Galea, Nicola
Dominici, Lorenzo
Verardo, Romina
Alfarano, Maria
Scialla, Rossella
Richetta, Antonio Giovanni
author_facet Frustaci, Andrea
Galea, Nicola
Dominici, Lorenzo
Verardo, Romina
Alfarano, Maria
Scialla, Rossella
Richetta, Antonio Giovanni
author_sort Frustaci, Andrea
collection PubMed
description (1) Background: Psoriasis (PS) is a common immune-mediated disease of the skin with possible extension to joints, aorta and eye. Myocardial inflammation has rarely been suggested. (2) Aims: Report of PS-related myocarditis. (3) Methods and Results: One hundred consecutive patients with PS were screened for cardiac involvement. Among them, five male patients (aged 56 ± 9.5 years) with a moderate–severe form of PS showed dilated cardiomyopathy (LVEF < 35%) with normal coronary arteries and valves. They underwent a left-ventricular endomyocardial biopsy for evaluation of myocardial substrate. Endomyocardial samples were processed for histology and immunohistochemistry, including myocardial expression of Toll-Like Receptor 4 (TLR4) and interleukin-17A (IL-17A), which play a major role in PS pathogenesis. Real-time PCRs were carried out for cardiotropic viruses, and Western blot analysis was conducted for myocardial expression of IL-17A. Patients’ sera were tested for anti-heart autoantibodies. Active lymphocytic myocarditis was revealed in all five patients, characterized by an absence of viral genomes with PCR, positive anti-heart autoantibodies, overexpression of TLR-4 and enhancement of IL-17-A during western blot analysis, showing a 2.48-fold increase in psoriatic myocarditis compared with no psoriatic myocarditis and a six-fold increase compared to myocardial controls. Treatment included combination of prednisone (1 mg/kg daily for 4 weeks, tapered to 0.33 mg/kg) and azathioprine (2 mg/kg, daily) in 3 pts or secukinumab (SK, 150 mg/weekly for 4 weeks followed by 150 mg/monthly) in 2 pts for 6 months. LVEDD and LVEF improved in the first 3 pts (−14% and + 118%, respectively), while they completely recovered (LVEF > 50%) in the last 2 pts on SK. (4) Conclusions: IL-17A-related myocarditis can occur in up to 5% of patients with PS. It manifests as progressive dilated cardiomyopathy. It may completely recover following SK administration.
format Online
Article
Text
id pubmed-10299195
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102991952023-06-28 Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration Frustaci, Andrea Galea, Nicola Dominici, Lorenzo Verardo, Romina Alfarano, Maria Scialla, Rossella Richetta, Antonio Giovanni J Clin Med Article (1) Background: Psoriasis (PS) is a common immune-mediated disease of the skin with possible extension to joints, aorta and eye. Myocardial inflammation has rarely been suggested. (2) Aims: Report of PS-related myocarditis. (3) Methods and Results: One hundred consecutive patients with PS were screened for cardiac involvement. Among them, five male patients (aged 56 ± 9.5 years) with a moderate–severe form of PS showed dilated cardiomyopathy (LVEF < 35%) with normal coronary arteries and valves. They underwent a left-ventricular endomyocardial biopsy for evaluation of myocardial substrate. Endomyocardial samples were processed for histology and immunohistochemistry, including myocardial expression of Toll-Like Receptor 4 (TLR4) and interleukin-17A (IL-17A), which play a major role in PS pathogenesis. Real-time PCRs were carried out for cardiotropic viruses, and Western blot analysis was conducted for myocardial expression of IL-17A. Patients’ sera were tested for anti-heart autoantibodies. Active lymphocytic myocarditis was revealed in all five patients, characterized by an absence of viral genomes with PCR, positive anti-heart autoantibodies, overexpression of TLR-4 and enhancement of IL-17-A during western blot analysis, showing a 2.48-fold increase in psoriatic myocarditis compared with no psoriatic myocarditis and a six-fold increase compared to myocardial controls. Treatment included combination of prednisone (1 mg/kg daily for 4 weeks, tapered to 0.33 mg/kg) and azathioprine (2 mg/kg, daily) in 3 pts or secukinumab (SK, 150 mg/weekly for 4 weeks followed by 150 mg/monthly) in 2 pts for 6 months. LVEDD and LVEF improved in the first 3 pts (−14% and + 118%, respectively), while they completely recovered (LVEF > 50%) in the last 2 pts on SK. (4) Conclusions: IL-17A-related myocarditis can occur in up to 5% of patients with PS. It manifests as progressive dilated cardiomyopathy. It may completely recover following SK administration. MDPI 2023-06-12 /pmc/articles/PMC10299195/ /pubmed/37373705 http://dx.doi.org/10.3390/jcm12124010 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Frustaci, Andrea
Galea, Nicola
Dominici, Lorenzo
Verardo, Romina
Alfarano, Maria
Scialla, Rossella
Richetta, Antonio Giovanni
Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration
title Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration
title_full Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration
title_fullStr Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration
title_full_unstemmed Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration
title_short Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration
title_sort interleukin-17a-correlated myocarditis in patients with psoriasis: cardiac recovery following secukinumab administration
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299195/
https://www.ncbi.nlm.nih.gov/pubmed/37373705
http://dx.doi.org/10.3390/jcm12124010
work_keys_str_mv AT frustaciandrea interleukin17acorrelatedmyocarditisinpatientswithpsoriasiscardiacrecoveryfollowingsecukinumabadministration
AT galeanicola interleukin17acorrelatedmyocarditisinpatientswithpsoriasiscardiacrecoveryfollowingsecukinumabadministration
AT dominicilorenzo interleukin17acorrelatedmyocarditisinpatientswithpsoriasiscardiacrecoveryfollowingsecukinumabadministration
AT verardoromina interleukin17acorrelatedmyocarditisinpatientswithpsoriasiscardiacrecoveryfollowingsecukinumabadministration
AT alfaranomaria interleukin17acorrelatedmyocarditisinpatientswithpsoriasiscardiacrecoveryfollowingsecukinumabadministration
AT sciallarossella interleukin17acorrelatedmyocarditisinpatientswithpsoriasiscardiacrecoveryfollowingsecukinumabadministration
AT richettaantoniogiovanni interleukin17acorrelatedmyocarditisinpatientswithpsoriasiscardiacrecoveryfollowingsecukinumabadministration